Investment Banking
About Stifel Investment Banking
A premier investment bank with a broad set of capabilities
Stifel is a full-service investment bank with deep industry experience. We serve as strategic advisor to entrepreneurs, family-owned businesses, private equity groups, and leading public and private corporations in North America, Europe, Asia, and Latin America.
Our more than 600 investment banking professionals stand ready to provide the insight and expertise you require. Our integrated approach allows us to deliver the full capabilities of Stifel’s institutional capital markets platform and retail brokerage network, which are among the most highly regarded in the industry.
Learn how Stifel has delivered unbiased, thoughtful advice to clients this year in our Spring Investment Banking Newsletter.
Download PDFIndustry Coverage
Serving companies through specialized expertise and strong relationships within our core industries.
Product Coverage
Our full-service product offering and the expertise of over 700 bankers allows Stifel to provide solutions that meet all of our clients’ evolving needs.
Notable Transactions
C$ 325,000,000
Sole Bookrunner
Building Products | April 2021
$ 312,000,000
Advisor to Buyer
Energy & Natural Resources | April 2021
Advisor to Seller
Industrial Technology | April 2021
Advisor to Seller
Software | April 2021
Advisor to Seller
Retail | April 2021
C$ 75,000,000
Joint Bookrunner
Building Products | April 2021
Advisor to Seller
Engineering & Construction, and Infrastructure | April 2021
Advisor to Seller
Engineering & Construction, and Infrastructure | April 2021
$ 98,325,000
Joint Bookrunner
Biopharma | April 2021
Advisor to Seller
Software | April 2021
£ 30,000,000
Advisor to Seller
Retail | April 2021
$ 100,912,500
Joint Bookrunner
Medtech | April 2021
$ 72,680,000
Left Bookrunner
Packaging | April 2021
Advisor to Seller
Building Products | April 2021
Joint Bookrunner
Real Estate | April 2021
$ 177,023,991
Joint Bookrunner
Real Estate | April 2021
$ 646,875,000
Joint Bookrunner
Tools & Diagnostics | April 2021
Advisor to Seller
Tech-Enabled Services | April 2021
$ 550,000,000
Joint Bookrunner
Biopharma | April 2021
£ 7,454,727
NOMAD and Sole Bookrunner
Software | March 2021
$ 103,500,000
Joint Bookrunner
Biopharma | March 2021
$ 50,652,000
Left Bookrunner
Biopharma | March 2021
Advisor to Seller
Software | March 2021
$ 75,000,000
Left Bookrunner
Energy & Natural Resources | March 2021
$ 920,000,000
Joint Bookrunner
Engineering & Construction, and Infrastructure | March 2021
€ 218,500,000
Joint Bookrunner
Biopharma | March 2021
Advisor to Seller
Software | March 2021
$ 700,000,000
Joint Bookrunner
Real Estate, Gaming & Leisure | March 2021
$ 230,000,000
Joint Bookrunner
Biopharma | February 2021
$ 210,000,000
Left Bookrunner
Software | February 2021
$ 262,500,000
Joint Bookrunner
Gaming & Leisure | January 2021
$ 400,000,000
Joint Bookrunner
Metals & Mining | January 2021
$ 2,000,000,000
Financial Advisor
Consumer Products | December 2020
Financial Advisor
Automotive Aftermarket | December 2020
Advisor to Seller
Tech-Enabled Services | December 2020
$ 993,000,000
Financial Advisor
Capital Goods | December 2020
$ 1,841,000,000
Financial Advisor
Electronics & Industrial Technology | December 2020
$ 500,000,000
Senior Co-Manager
Energy & Natural Resources | December 2020
$ 555,450,000
Joint Bookrunner
Biopharma | December 2020
$ 199,300,000
Joint Bookrunner
Cannabis | December 2020
$ 750,000,000
Joint Bookrunner
Tools & Diagnostics | December 2020
$ 3,321,000,000
Joint Financial Advisor
Automotive OEMs & Suppliers | November 2020
$ 93,987,050
Left Bookrunner
Gaming & Leisure | November 2020
$ 333,500,000
Joint Bookrunner
Gaming & Leisure | November 2020
$ 1,863,000,000
Joint Bookrunner
Tools & Diagnostics | November 2020
$ 933,000,000
Advisor to North American
Engineering & Construction, and Infrastructure | October 2020
$ 321,100,000
Advisor to Seller
Internet & Digital Media | October 2020
$ 700,000,000
Joint Bookrunner
Real Estate | October 2020
$ 86,250,000
Joint Bookrunner
Metals & Mining | October 2020
$ 1,898,938,296
Joint Financial Advisor
Biopharma | October 2020
£ 1,800,000,000
Financial Advisor
Financial Institutions | September 2020
$ 1,150,000,000
Advisor to Seller
Software | April 2020